Detailed profiling of anti-desmoglein autoantibodies identifies anti-Dsg1 reactivity as a key driver of disease activity and clinical expression in pemphigus vulgaris

References

• Amagai, M., V. Klaus-Kovtun, and J. R. Stanley. 1991. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 67: 869–877
   PubMed Web of Science ®Google Scholar
• Kalantari-Dehaghi, M., G. J. Anhalt, M. J. Camilleri, et al. 2013. Pemphigus vulgaris autoantibody profiling by proteomic technique. PloS. One. 8: e57587
   PubMed Web of Science ®Google Scholar
• Calkins, C. C., S. V. Setzer, J. M. Jennings, et al. 2006. Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. J. Biol. Chem. 281: 7623–7634
   PubMed Web of Science ®Google Scholar
• Amagai, M., A. R. Ahmed, Y. Kitajima, et al. 2006. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just “witnesses of disease”? Exp. Dermatol. 15: 815–831
   PubMed Web of Science ®Google Scholar
• Kurzen, H., and S. Brenner. 2006. Significance of autoimmunity to non-desmoglein targets in pemphigus. Autoimmunity. 39: 549–556
   PubMed Web of Science ®Google Scholar
• Nguyen, V. T., A. Ndoye, L. D. Shultz, et al. 2000. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J. Clin. Investig. 106: 1467–1479
   PubMed Web of Science ®Google Scholar
• Amagai, M., K. Tsunoda, D. Zillikens, et al. 1999. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J. Am. Acad. Dermatol. 40: 167–170
   PubMed Web of Science ®Google Scholar
• Mahoney, M. G., Z. Wang, K. Rothenberger, et al. 1999. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J. Clin. Investig. 103: 461–468
   PubMed Web of Science ®Google Scholar
• Harman, K. E., P. T. Seed, M. J. Gratian, et al. 2001. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br. J. Dermatol. 144: 775–780
   PubMed Web of Science ®Google Scholar
• Jamora, M. J., D. Jiao, and J. C. Bystryn. 2003. Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris. J. Am. Acad. Dermatol. 48: 976–977
   PubMedGoogle Scholar
• Ding, X., V. Aoki, J. M. Mascaro, Jret al. 1997. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J. Investig. Dermatol. 109: 592–596
   PubMed Web of Science ®Google Scholar
• Yoshida, K., Y. Takae, H. Saito, et al. 2005. Cutaneous type pemphigus vulgaris: a rare clinical phenotype of pemphigus. J. Am. Acad. Dermatol. 52: 839–845
   PubMed Web of Science ®Google Scholar
• Harman, K. E., M. J. Gratian, B. S. Bhogal, et al. 2000. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br. J. Dermatol. 143: 343–348
   PubMed Web of Science ®Google Scholar
• Cheng, S. W., M. Kobayashi, K. Kinoshita-Kuroda, et al. 2002. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br. J. Dermatol. 147: 261–265
   PubMedGoogle Scholar
• Sharma, V. K., H. R. Prasad, S. Khandpur, and A. Kumar. 2006. Evaluation of desmoglein enzyme-linked immunosorbent assay (ELISA) in Indian patients with pemphigus vulgaris. Int. J. Dermatol. 45: 518–522
   PubMed Web of Science ®Google Scholar
• Daneshpazhooh, M., C. Chams-Davatchi, A. Khamesipour, et al. 2007. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. J. Eur. Acad. Dermatol. Venereol. JEADV 21: 1319–1324
   PubMed Web of Science ®Google Scholar
• Abasq, C., H. Mouquet, D. Gilbert, et al. 2009. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch. Dermatol. 145: 529–535
   PubMedGoogle Scholar
• Belloni-Fortina, A., D. Faggion, B. Pigozzi, et al. 2009. Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up. Clin. Dev. Immunol. 2009: 187864
   PubMedGoogle Scholar
• Herrero-Gonzalez, J. E., P. Iranzo, D. Benitez, et al. 2010. Correlation of immunological profile with phenotype and disease outcome in pemphigus. Acta Dermato-venereolog. 90: 401–405
   PubMed Web of Science ®Google Scholar
• Schmidt, E., C. Dahnrich, A. Rosemann, et al. 2010. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp. Dermatol. 19: 458–463
   PubMed Web of Science ®Google Scholar
• Anand, V., S. Khandpur, V. K. Sharma, and A. Sharma. 2012. Utility of desmoglein ELISA in the clinical correlation and disease monitoring of pemphigus vulgaris. J. Eur. Acad. Dermatol. Venereol. JEADV 26: 1377–1383
   Google Scholar
• Luftl, M., A. Stauber, A. Mainka, et al. 2003. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br. J. Dermatol. 149: 598–605
   PubMedGoogle Scholar
• Sardana, K., V. K. Garg, and P. Agarwal. 2013. Is there an emergent need to modify the desmoglein compensation theory in pemphigus on the basis of Dsg ELISA data and alternative pathogenic mechanisms? Br. J. Dermatol. 168: 669–674
   Google Scholar
• Murrell, D. F., S. Dick, A. R. Ahmed, et al. 2008. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J. Am. Acad. Dermatol. 58: 1043–1046
   PubMed Web of Science ®Google Scholar
• Sinha, A. A. 2012. Constructing immunoprofiles to deconstruct disease complexity in pemphigus. Autoimmunity 45: 36–43
   PubMed Web of Science ®Google Scholar
• Daneshpazhooh, M., K. Kamyab, M. S. Kalantari, et al. 2014. Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris. Clin. Exp. Dermatol. 39: 41–47
   PubMed Web of Science ®Google Scholar
• Reguiai, Z., T. Tabary, M. Maizieres, and P. Bernard. 2012. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J. Am. Acad. Dermatol. 67: 623–629
   PubMed Web of Science ®Google Scholar
• Colliou, N., D. Picard, F. Caillot, et al. 2013. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci. Transl. Med. 5: 175ra130
   Google Scholar
• Herbst, A., and J. C. Bystryn. 2000. Patterns of remission in pemphigus vulgaris. J. Am. Acad. Dermatol. 42: 422–427
   PubMed Web of Science ®Google Scholar
• Saha, M., B. Bhogal, M. M. Black, et al. 2014. Prognostic factors in pemphigus vulgaris and pemphigus foliaceus. Br. J. Dermatol. 170: 116–122
   Google Scholar